Plant-expressed HA as a seasonal influenza vaccine candidate (Q43830644)

27 November 2017

Plant-expressed HA as a seasonal influenza vaccine candidate (English)

1 reference

27 November 2017

1 reference

1 reference

11

Vidadi Yusibov

1 reference

27 November 2017

Yoko Shoji

1

1 reference

27 November 2017

Jessica A Chichester

2

1 reference

27 November 2017

Hong Bi

3

1 reference

27 November 2017

Konstantin Musiychuk

4

1 reference

27 November 2017

Patricia de la Rosa

5

1 reference

27 November 2017

Lauren Goldschmidt

6

1 reference

27 November 2017

April Horsey

7

1 reference

27 November 2017

Natalia Ugulava

8

1 reference

27 November 2017

Gene A Palmer

9

1 reference

27 November 2017

Vadim Mett

10

1 reference

27 November 2017

language of work or name

English

0 references

publication date

9 April 2008

1 reference

27 November 2017

1 reference

27 November 2017

26

1 reference

27 November 2017

23

1 reference

27 November 2017

2930-2934

1 reference

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Influenza-associated hospitalizations in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Large-scale manufacture and use of recombinant VP2 vaccine against infectious bursal disease in chickens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Human immune response to a plague vaccine comprising recombinant F1 and V antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Plant based HIV-1 vaccine candidate: Tat protein produced in spinach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

The development of a plant-based vaccine for measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Immunogenicity of a subunit vaccine against Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

A plant-produced plague vaccine candidate confers protection to monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Different response requirements for IFNgamma production in ELISPOT assays by CD4+ T cells from mice early and late after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Quillaja saponin can modulate ovalbumin-induced IgE allergic responses through regulation of Th1/Th2 balance in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Recent advances in veterinary vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.045

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.03.045

1 reference

27 November 2017

1 reference